Skip to main content
. Author manuscript; available in PMC: 2015 Jan 28.
Published in final edited form as: Melanoma Res. 2014 Apr;24(2):150–157. doi: 10.1097/CMR.0000000000000050

Fig. 5.

Fig. 5

Overall survival (OS) by autoimmunity at 1-year landmark time among stage III patients in E1694. Including both study arms (high-dose interferon and vaccine) and adjusting for treatment, there was no significant association with OS (hazard ratio=0.92, 95% confidence interval: 0.72–1.39; P=0.92).